Clinical Trials Logo
  1. Home
  2. Posterior Uveitis
  3. NCT03971279
  4. Details
NCT03971279 Clinical Trial

Dexamethasone Intravitreal Implant (Ozurdex®) for Recurrent Vogt-Koyanagi-Harada (VKH) Disease Posterior Uveitis

Posterior Uveitis Clinical Trial

Official title:
Long Term Efficacy of Dexamethasone Intravitreal Implant (Ozurdex®) in Treatment of Recurrent VKH Uveitis

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03971279
Other study ID # hamaky2
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2017
Est. completion date November 22, 2019

Study information
Verified date November 2019
Source Benha University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

VKH disease is a vision threatening condition.The investigators consider that ozurdex intravitreal implant is an effective line of treatment in recurrent VKH posterior uveitis.

Description:

Baseline ,and postoperative 1 ,6 ,12 and 24 months full ophthalmic examination was done.

Procedure included intravitreal injection of Dexamethasone implant 0.7 mg (Ozurdex(®); Allergan, Inc, Irvine, CA)

Recruitment information / eligibility
Status Completed
Enrollment 16
Est. completion date November 22, 2019
Est. primary completion date November 22, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Recurrent VKH posterior uveitis

Exclusion Criteria:

- retinal pathology, other causes of posterior uveitis

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Dexamethasone Ophthalmic implant
intravitreal injection of ozurdex implant

Locations
Country Name City State
United Arab Emirates INMC Abu Dhabi

Sponsors (1)
Lead Sponsor Collaborator
Benha University

Country where clinical trial is conducted

United Arab Emirates, 

Outcome
Type Measure Description Time frame Safety issue
Primary Best corrected visual acuity (BCVA) Change in BCVA 2 years
Secondary optical coherence tomography (OCT) foveal thickness changes in central foveal thickness 2 years
See also
  Status Clinical Trial Phase
Withdrawn NCT01280669 - Intravitreal Sirolimus as Therapeutic Approach to Uveitis Phase 2
Completed NCT00570830 - Retisert and Cataract Surgery in Patients With Severe Uveitis N/A
Completed NCT00167583 - Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet`s Disease (INCYTOB) Phase 3
Recruiting NCT05153057 - Birdshot Chorioretinopathy : Prospective Follow-up and Immunogenetic Studies(CO-BIRD)
Not yet recruiting NCT04126850 - Pilot Project: The Amplicon and Metatranscriptomic Study of Intra and Extra Intestinal Microbiome in Non-infectious Uveitis Disease
Completed NCT00333814 - A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis Phase 2/Phase 3
Active, not recruiting NCT01717170 - Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study Phase 1/Phase 2
Completed NCT02764697 - Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients Phase 4
Recruiting NCT00407316 - Quality of Life and Visual Function in Uveitis Patients Phase 0
Completed NCT02746991 - Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis Phase 3
Completed NCT00908466 - Sirolimus as Therapeutic Approach to Uveitis Phase 1
Completed NCT00615693 - Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis Phase 2
Completed NCT01789320 - Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis Phase 1/Phase 2